Address
14 Schoolhouse Road
Somerset, NJ 08873
United States of America (the)
Phone
732 537 6200
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
17000
First IPO Date
July 31, 2014
| Name | Title | Pay | Year Born |
| Alessandro Maselli | President, Chief Executive Officer & Director | 3.11M | 1972 |
| Aristippos Gennadios | Group President of Pharma & Consumer Health Segment | 799,263 | 1966 |
| Ricky Hopson | President, Division Head for BioProduct Delivery & Chief of Staff | 876,328 | 1976 |
| Lisa Evoli | Senior Vice President & Chief Human Resources Officer | 939,003 | 1970 |
| David McErlane | Group President of Biologics Segment | 1.01M | 1973 |
| John J. Greisch | Executive Chairman of the Board | 1.54M | 1955 |
| Matti Masanovich | Senior Vice President & Chief Financial Officer | 1.65M | 1972 |
| Joseph A. Ferraro | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary | 0 | 1978 |
| Paul Surdez | Vice President of Investor Relations | 0 | N/A |
| Dejan Lamesic | Head of Formulation & Process Development | 0 | N/A |
| Michael J. Grippo | Senior Vice President of Strategy & Corporate Development | 0 | 1969 |
| Trish Hunt | President & Division Head for Consumer Health | 0 | 1970 |
| Charles Lickfold | Senior Vice President & Chief Information Officer | 0 | 1974 |
| Michael J. Hatzfeld Jr. | Vice President & Chief Accounting Officer | 0 | 1973 |
| Tom Hawkeswood | President & Division Head of Pharma Product Delivery | 0 | 1968 |
Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.